



FDA approves Novartis' PLUVICTO in combination with an ARPI to treat metastatic hormone-sensitive prostate cancer

(FDA, Approval)



EC approves AstraZeneca and Daiichi Sankyo's DATROWAY as monotherapy to treat adults with unresectable or metastatic TNBC

(EU, Approval)



Pfizer and BioNTech gets marketing authorization from the EC for the 2026-2027 COVID-19 vaccine formulation to prevent COVID-19 in individuals 6 months of age and older

(EU, Approval)



Biocon receives Health Canada approval for the YESINTEK autoinjector 45 mg/0.05 mL and 90 mg/mL, allowing customized treatment approaches for psoriasis

(Health Canada, Approval)



(FDA, EMA, Priority Review)



**FRESENIUS
KABI**

FDA and EMA accepts Fresenius Kabi's BLA and MAA for PB016 for review, a lyophilized vial for IV to treat adults with moderately to severely active ulcerative colitis and Crohn's disease

(FDA, Priority Review)

Johnson&Johnson

FDA grants Priority Review to J&J's sBLA for amivantamab and hyaluronidase-lpuj SC for adults with metastatic HNSCC

(Acquisition)

Johnson&Johnson

J&J acquires Firefly Bio for \$1B, expanding its oncology portfolio and advancing targeted therapy development for difficult-to-treat solid tumors, including KRAS-driven cancers

(Collaboration)

Johnson&Johnson

J&J collaborates with Sail Biomedicines for an initial payment of \$785M to advance its immune-mediated disease program with CAR-T platform technology



(Launch)



Biocon launches YESAFIL, a biosimilar in the US, indicated to treat various types of ophthalmology conditions

(Phase 3, Results)



Pfizer's Ph3 TRANQUILLO trials demonstrate that 50 mg and 100 mg LITFULO deliver clinically meaningful VASl improvements over placebo in nonsegmental vitiligo

(Phase 3, Results)



ViiV Healthcare and Shionogi's Ph3b VOGUE study shows DOVATO achieves non-inferior efficacy to BIKTARVY in treatment-naïve HIV adults, including high viral loads or low CD4+, with zero treatment-emergent resistance

